

Comparison of three methods to stabilize bronchoalveolar lavage cells for flowcytometric analysis

Harrie H. M. Eidhof¹  | Jan W. Gratama² | A. H. Leontine Mulder^{1,3}

¹Department of Clinical Chemistry and Laboratory Medicine, Medlon BV, Enschede, The Netherlands

²Department of Medical Oncology, Erasmus MC, Rotterdam, The Netherlands

³Ziekenhuis Groep Twente, Almelo, The Netherlands

Correspondence

A. H. Leontine Mulder, Medlon BV,
Koningsplein 1, 7512KZ Enschede, The
Netherlands.
Email: l.mulder@medlon.nl

Abstract

Background: Flowcytometric analysis of lymphocytes and their subpopulations in bronchoalveolar lavages (BAL) can support the diagnosis of interstitial lung diseases. This analysis should be done within 4 hr after lavage due to rapid cell deterioration. We tested three methods in order to stabilize for at least 28 days the BAL cell populations to allow delayed flowcytometric analysis in order to facilitate external quality assurance (EQA).

Methods: We compared an in-house, dual-step stabilization method for BAL cells with results of two different commercial available stabilization reagents: TransFix® and Streck Cell Preservative™. All three methods were compared with native BAL cells as reference. BAL samples from six patients were tested on six occasions following stabilization from 1 to 28 days by flow cytometry.

Results: Following stabilization and storage at 4°C, BAL cell suspensions had stable light scatter patterns and lymphocyte subsets. As expected, rapid deterioration of cells was seen with native BAL cells. The stabilized lavages showed more stable counts of WBC and lymphocyte populations with only minor differences found between the three methods.

Conclusions: If analysis of the BAL cells is performed more than 24 hr after the lavage, stabilized BAL cells are superior to native cells. The in-house method can be used for EQA purposes with stability for at least 28 days. The TransFix and Streck methods might be useful for postponed diagnostic analysis of lavage cells but did not meet our 28 days criterion defined needed for EQA purposes.

KEYWORDS

bronchoalveolar lavage, external quality survey, lymphocyte subsets, stabilization

1 | INTRODUCTION

Bronchoalveolar lavage (BAL) is performed as a diagnostic procedure on patients with interstitial lung disease. The right middle lobe of the patient's lungs is washed with isotonic saline solution and the aspirated solution analyzed for cell concentration, morphology, differentiation of cells and immunophenotype of lymphocytes. Results may add to diagnosis, especially when suspected for sarcoidosis, extrinsic allergic alveolitis, or idiopathic pulmonary fibrosis (BAL Cooperative Group

Steering Committee, 1990; Barry, Condez, Johnson, & Janossy, 2002; Lannuzzi, Rybicki, & Teirstein, 2007; Meyer et al., 2012; Welker, Jörres, Costabel, & Magnussen, 2004). Since the cells in the lavage fluid are prone to rapid deterioration, the BAL fluid is immediately kept on ice and must be analyzed within 4 hr after lavage (BAL Cooperative Group Steering Committee, 1990; Klech & Hutter, 1990). The short time required between obtaining the fluid and performing the analysis (Meyer et al., 2012) can be a problem if flowcytometric analysis cannot be done at the site the lavage is being performed.

BAL cell analysis with immunophenotyping of lymphocytes is currently (2020) done routinely in the Netherlands and Belgium, by more than 40 laboratories. Our laboratory recognized the need for an external quality assurance (EQA) survey, in order to know the interlaboratory variation. However, the deterioration of lavage cells hampers the organization and execution of an EQA program. In order to set up a quality survey with BAL cells we developed a method to stabilize the BAL cells. Our goal was to stabilize the cells in such a way, that the original light scatter and immunophenotypic characteristics of cells in BAL are preserved for a minimum of 28 days and the obtained results remain similar to those of fresh cells. A period of 28 days gives EQA participants sufficient time to analyze the samples and interpret the results, with the opportunity to request a repeat sample if needed. In this article, we present and discuss the comparison of native lavage cells versus stabilized cells using our in-house method and two commercially available fixation reagents, that is, TransFix and Streck Cell Preservative (Streck CP).

2 | MATERIALS AND METHODS

2.1 | Specimens

BAL cells were used from lavages from six different patients that were submitted to our hospital laboratory for analysis and contained more than 10×10^6 nucleated cells. Cell concentrations ranged from 0.150 to 0.825×10^9 /L and protein concentrations from 0.131 to 0.568 g/L. After sampling, the lavages were kept on ice. Stabilizations were done within 4 hr. All samples were anonymized at the beginning of the study.

2.2 | Stabilization of BAL cells

Five milliliters of native filtered (through loose gauze) BAL material was stored at 2–8°C in a polystyrene tube and used as native BAL material during 28 days. For our in-house method, we collected cells from 10 ml filtered BAL fluid by centrifugation 10 min at 400g at 2–8°C. The cell pellet was suspended in Gibco RPMI 1640 medium (Thermo Fisher Scientific, Breda, the Netherlands) with 5% fetal calf

serum (Gibco) and diluted to a cell concentration of 5×10^9 /L. Stabilization was done by adding an equal volume of fixation reagent (1% formaldehyde (10%, ultrapure EM grade, Polysciences, Inc., Warrington, PA) in phosphate buffered saline (PBS) (Gibco) and incubation at room temperature (RT) for 2 hr with gentle mixing. After a centrifugation step (5 min at 400g, RT), the cell pellet was suspended in storage solution (3.34% bovine serum albumin [BSA 22%, Ortho Clinical Diagnostics, Beersse, Belgium] in PBS) at a cell concentration of 5×10^9 /L. This cell suspension was stored at 2–8°C. Streck Cell Preservative tubes (Streck, Omaha, NE) were used according to the instructions of the manufacturer. TransFix®/EDTA cerebrospinal fluid (CSF) sample storage tubes (Cytomark, Buckingham, UK) were used with a modification for the TransFix procedure (i.e., 5 ml of filtered native BAL material to 500 µl TransFix [a kind gift of Cytomark] instead of the 200 µl as per the CSF protocol).

2.3 | Flow cytometry

On Days 1, 3, 7, 14, 21, and 28, we tested the patient samples either native or stabilized with the in-house method, TransFix, and Streck CP techniques by flowcytometric analysis. Briefly, we took 500 µl samples of each of the well-mixed tubes (TransFix, Streck CP, or native) for centrifugation at room temperature (5 min at 400g). Cell pellets were suspended in 50 µl of PBS supplemented with 0.5% BSA. From the in-house tube, 50 µl was used directly. To these cell suspensions 30 µl BAL monoclonal mix was added (Table 1), vortexed and incubated for 20 min at RT in the dark. After Ammonium Chloride lysis (2 ml) and centrifugation, the cell pellet was suspended in 800 µl IsoFlow™ Sheath Fluid (Beckman Coulter, Woerden, The Netherlands). The cells were analyzed on a Navios flow cytometer (Beckman Coulter) within 30 min. Analysis of WBC was done by pipetting 50 µl of in-house cell suspension or 200 µl of suspensions from TransFix, Streck CP, native cells to 5 µl CD45KO monoclonal antibody (Beckman Coulter). After 20 min incubation in the dark, 500 µl IsoFlow Sheath Fluid and 50 µl of Flow Count Fluorosphere beads (Beckman Coulter) were added, mixed, and analyzed. Flowcytometric data analysis was performed with Kaluza software (Beckman Coulter). All lymphocyte subsets were calculated on CD45/SSC gated lymphocytes.

Recovery of WBC, % lymphocytes or lymphocyte subsets was calculated relative to Day 0, with the exception of the recovery of the

Antigen	Fluorochrome	Clone	Manufacturer
CD3	APC-Alexa Fluor 750	UCHT1	Beckman Coulter
CD4	FITC	13B8.2	Beckman Coulter
CD8	APC	B9.11	Beckman Coulter
CD16	PC7	3G8	Beckman Coulter
CD56	PC7	N901 (NKH-1)	Beckman Coulter
CD45	KO	B36294 2014-02-19 GB	Beckman Coulter
CD19	HV450	HIB19	BD Biosciences
CD103	PE	7/2010 23-5646-01	BD Biosciences

TABLE 1 Monoclonal antibodies used

WBC fixed with the in-house method, this was calculated relative to Day 1.

2.4 | Statistical analysis

Statistical analysis was done with SPSS software using repeated measures ANOVA (Dawson & Trapp, 2001).

3 | RESULTS

Analysis of the flowcytometric data showed that for all markers studied, a good separation of negative from positive could be obtained

regardless of the stabilization method used. Examples of the CD45+ side scatter plots of native and stabilized lavages at Day 7 are shown in Figure 1. Mean results of the six BAL samples at the studied time intervals are shown in Figure 2 for all 10 parameters of interest. The changes in time between the groups were significant for all parameters except the T lymphocytes (defined as CD3+) and %CD103+ within CD4+ lymphocytes. This significant change was mainly due to the deterioration of the native untreated samples. Exclusion of the native group in the statistical analysis resulted in a significant difference between the three stabilized groups for the T lymphocytes ($p = .05$) and CD8 lymphocytes ($p = .01$), in addition to FSC ($p < .01$) and SSC ($p < .01$) (Table 2).

To illustrate the stability and range of change for the different methods of cell preservation, the % WBC recovery between Days




FIGURE 1 CD45+ side scatter plots. (a) Native BAL Day 0, (b) native BAL Day 7, (c) in-house stabilized BAL Day 7, (d) TransFix stabilized BAL Day 7, and (e) Streck CP stabilized BAL Day 7 [Color figure can be viewed at wileyonlinelibrary.com]




FIGURE 2 Changes as function of storage time. Given is the recovery (%) on Y-axis at the different time points on the X-axis (days) for each stabilization method. (···) In-house; (---) TransFix; (- · -) Streck CP; (—) Native

1 and 28 are shown in Table 3. The range in WBC counts was wider for the Streck CP stabilized cells compared to the other two fixation methods (i.e., on average 69.3 for Streck vs, 27.3 for TransFix, and 18.6 for in-house; Table 3). The variation of the performed stainings on the stabilized cells using the CV(%) of six repetitive stainings is displayed in Table 4.

4 | DISCUSSION

We investigated whether or not stabilization of the BAL cells is possible when analysis by flow cytometry is required for the parameters of interest. Fixation of cells may result in changes of light scatter properties and in structures of antigens (Canonico et al., 2004; Stewart,

TABLE 2 Mean recovery at all timepoints

	In-house	TransFix	Streck CP	Native	<i>p</i> stabilized groups
WBC	95 (91–100)	85 (80–91)	87 (76–99)	61 (51–71)	.21
Lympho	109 (103–115)	92 (87–97)	93 (87–99)	67 (58–76)	.06
FSC	77 (73–80)	100 (97–102)	81 (77–84)	65 (57–72)	<.01
SSC	75 (72–79)	78 (74–81)	86 (83–88)	83 (80–86)	<.01
CD3+ cells	102 (100–105)	99 (97–101)	103 (101–105)	98 (95–101)	.05
CD3+ CD4+ cells	100 (98–103)	99 (97–101)	98 (96–100)	89 (86–93)	.58
CD3+ CD8+ cells	94 (89–99)	93 (90–97)	99 (95–102)	110 (103–117)	.01
CD19+ cells ^a	140 (115–165)	162 (135–189)	166 (137–195)	218 (172–263)	.87
CD3-CD16+,CD56+ cells	76 (70–82)	81 (75–88)	85 (79–92)	106 (91–120)	.27
CD103+ within CD4+	87 (80–94)	95 (91–98)	99 (95–103)	111 (103–119)	.54

Note: Shown are the mean percentages recovery relative to Day 0 per parameter over all timepoints with 95% confidence intervals. Mixed measures ANOVA *p* values are given over the stabilized groups.

^aFive out of six lavages contained only 1% CD19+ B cells.

TABLE 3 % WBC recovery relative to Day 0

	Day 1	Day 3	Day 7	Day 14	Day 21	Day 28
In-house	100 ^a	106 (100–113)	95 (88–102)	90 (73–106)	93 (84–101)	89 (81–97)
TransFix	95 (87–102)	85 (71–100)	91 (79–104)	74 (60–88)	82 (66–99)	71 (54–88)
Streck CP	95 (59–131)	74 (46–102)	89 (42–136)	83 (52–114)	91 (55–126)	79 (49–110)
Native	96 (64–127)	72 (53–91)	59(41–78)	39 (29–49)	34 (24–45)	26 (14–38)

^aSince the WBC number is affected by the stabilization method, the WBC data for this method are compared to Day 1 rather than to Day 0.

TABLE 4 CV(%) of results of staining after stabilization (*n* = 6)

Parameter	In-house	TransFix	Streck CP
WBC	5.4	7.8	6.8
% lymphocytes	1.2	2.9	5.1
FSC	1.3	1.6	4.8
SSC	2.8	4.8	3.4
% CD3+ cells	0.3	0.4	0.6
%CD3+ CD4+	0.3	0.2	0.6
%CD3+ CD8+	2.6	4.2	3.8
%CD103+ within CD4+	2.8	3.3	4.5
%CD3-CD16+, CD56+ cells	5.1	4.9	5.1
% CD19+ cells	3.5	1.6	2.8

Note: Given is the CV% of six repetitive stainings of stabilized BAL cells.

Villasmil, & Frampton, 2007) leading to changes in reactivity patterns with monoclonal antibodies. With the limited panel of antibodies we used (Table 1), we encountered no problems but when other antibodies are used, one has to validate if the antigen is still recognized after stabilization.

Our in-house fixation method is based on formaldehyde fixation in buffered conditions containing serum proteins. Formaldehyde was chosen because of its crosslinking rather than dehydrating properties. We chose to compare this method with commercially available

fixatives that are known to stabilize cells in fragile conditions as cerebrospinal fluid (CSF) (de Jongste et al., 2014) or fine needle aspirates. To our opinion these body fluids are similar to BAL fluid because of their low protein content.

Native lavage shows a very rapid deterioration of cell numbers making it not suitable for delayed analysis. When comparing only the stabilized samples, a significant difference within the three methods was found for the CD3+ lymphocytes and CD8+ lymphocytes. Although statistically a significant difference was found for the CD3+ lymphocytes, it can be seen from Table 2 that all three methods resulted in an almost 100% mean conservation of the CD3+ cell population. Recoveries for the stabilized CD3+ lymphocytes at the different time points varied from 97% to 105%. The TransFix method showed the best conservation and the lowest variance of the FSC. Regarding the CD8+ T cells the Streck CP reagent showed the best conservation with mean recovery closest to 100% and lowest variance. All stabilization methods influenced the side scatter (SSC), but this did not influence the gating of the leukocyte population. Technical variation of performed staining on stabilized cells as displayed in Table 4 was equal or sometimes slightly worse, but acceptable, compared to variation of the native material, where CV from the parameters are all <5% (data not shown). As can be seen from Figure 1, sometimes recovery reached values >100%, especially for the CD19+-cell population (all fixatives) and CD16+/CD56+-cell population (d3 and d7, native). The CD19+-cell population was <1%

in all but one lavage. Calculation of recoveries of such small populations resulted in values >100% (Figure 2). The increment in the CD3-CD16+,CD56+ population cannot be explained by inferior gating or contamination of this population since the sum of the CD3+, CD19+ and CD3-CD16+, CD56+ populations equals 100%. Hypothetically the CD3-CD16+CD56+ could be the population that deteriorates more slowly than the other populations under native conditions, resulting in a relative enrichment. CD103 expression was least conserved by the in-house method for which we have no explanation.

The in-house method is more time consuming and may give some risk on loss of cells with extra centrifugation and aspiration steps in the fixation procedure compared to the TransFix and Streck CP method. In addition due to the methodology of the in-house stabilization the WBC count of the lavage is standardized ($5 \times 10^9/L$) which makes this method not suitable for diagnostic evaluation of BAL. We developed the method in need of a stabilization method that made BAL suitable for an external quality survey. The fact that with this method cells can be brought to a desired cell concentration is indeed an attractive characteristic for quality survey purposes.

The original WBC count of lavages conserved with TransFix of Streck CP can be calculated back, making these reagents possibly suitable for stabilization of lavages in order to postpone the diagnostic analysis. In order to evaluate this possible benefit, we arbitrarily defined the following acceptance criteria: less than 15% change for leukocyte count, less than 10% change for cell populations >10% and less than 20% change for cell populations <10%. Applying these, the samples stabilized with TransFix fulfilled these criteria for 7 days, where most but not all samples stabilized with Streck CP did. However, a great variation of the WBC count was seen with some of the Streck CP stabilized lavages as can be seen in Table 3. This may be due to the fact that the samples stabilized with Streck CP are more diluted than with the other stabilization methods, and the original cell counts were low, ranging $0.150\text{--}0.825 \times 10^9/L$. This in combination with the small size of this pilot study makes that no statement can be made whether or not the Streck CP reagent can be used to stabilize BAL cells in order to postpone the diagnostic analysis although % lymphocyte subsets scored well. More samples need to be measured to obtain more solid information. Our study only monitored the stabilization of the lymphocyte populations and not the other leukocytes that can be present in BAL like neutrophils, eosinophils, or mast cells. Since each lavage has to be investigated for epithelial cells, macrophage inclusions, macrophage foam cells and on indication on asbestos particles, malignant cells, and so forth, always cytopsins are prepared. Cellular differentiation to obtain the percentage of nonlymphocyte leukocytes is routinely performed on the cytopsins. In case of postponed analysis the cytopsins can be made directly after obtaining the lavage, air-dried these can be conserved for weeks.

In conclusion, according to literature BAL cells are prone to rapid deterioration and a general advice is to analyze the cells within 4 hr

after sampling. Our results indeed show significant changes over time in WBC count, % lymphocytes, FSC, and % CD4, CD 8, CD16,56 or CD103 positive lymphocytes. This study was designed to compare our in-house method with commercially available stabilization products and to prove its suitability to obtain stabilized lavage cells for EQA purposes. ISO/IEC 17043:2010 states that samples selected for proficiency testing should be sufficiently stable to ensure that they will not undergo any significant change throughout the conduct of the proficiency testing, including storage and transport conditions. The 28 day stability of the cells with our in-house method meets this criterion, since the proficiency round with participants only in The Netherlands and Belgium is completed within this period. In this pilot study the commercially available reagents did not fulfill this criterion. However, when flowcytometric diagnostic analysis of the BAL cells is not possible within 4 hr, Transfix stabilization might be used to analyze up to 7 days after sampling if immediate stabilization is performed and storage takes place at $2\text{--}8^\circ\text{C}$. As stated above, for the Streck CP reagent, more samples need to be measured.

ACKNOWLEDGMENTS

We kindly acknowledge Professor David Barnett, PhD, FRCPATH, for critically reviewing the manuscript and suggestions for improvements. We kindly acknowledge Mrs. M. Vermeer, Clinical Epidemiologist, Ziekenhuis Groep Twente for support on statistical analysis.

ORCID

Harrie H. M. Eidhof  <https://orcid.org/0000-0002-7880-2615>

REFERENCES

- BAL Cooperative Group Steering Committee. (1990). Bronchoalveolar lavage constituent in healthy individuals, idiopathic pulmonary fibrosis, selected comparison groups. *The American Review of Respiratory Disease*, 41, 169–202.
- Barry, S. M., Condez, A., Johnson, M. A., & Janossy, G. (2002). Determination of bronchoalveolar lavage leukocyte populations by flow cytometry in patients investigated for respiratory disease. *Cytometry*, 50, 291–297.
- Canonica, B., Zamai, L., Burattinib, V., Grangerd, F., Mannelloc, P., Gobbib, C., ... Papa, S. (2004). Evaluation of leukocyte stabilization in TransFix®-treated blood samples by flow cytometry and transmission electron microscopy. *Journal of Immunological Methods*, 295, 67–78.
- Dawson, B., & Trapp, R. G. (2001). *Basic and clinical biostatistics* (3rd ed., p. 399). New York: McGraw Hill.
- de Jongste, A. H., Kraan, J., van den Broek, P. D., Brooimans, R. A., Bromberg, J. E., van Montfort, K. A., ... Gratama, J. W. (2014). Use of TransFix TM cerebrospinal fluid storage tubes prevents cellular loss and enhances flow cytometric detection of malignant hematological cells after 18 hours of storage. *Cytometry Part B*, 86B, 272–279.
- Klech, H., & Hutter, C. (1990). Clinical guidelines and indications for bronchoalveolar lavage (BAL). Report of the European Society of Pneumology Task Group on BAL. *The European Respiratory Journal*, 3, 937–974.
- Lannuzzi, M. C., Rybicki, B. A., & Teirstein, A. S. (2007). Review article sarcoidosis. *The New England Journal of Medicine*, 357, 2153–2165.
- Meyer, K. C., Raghu, G., Baughman, R. P., Brown, K. K., Costabel, U., du Bois, R. M., ... Brent Wood, B. (2012). An Official American Thoracic Society Clinical Practice Guideline: The clinical utility of bronchoalveolar

- lavage cellular analysis in interstitial lung disease. *American Journal of Respiratory and Critical Care Medicine*, 185, 1004–1014.
- Stewart, J. C., Villasmil, M. N., & Frampton, M. W. (2007). Changes in fluorescence intensity of selected leukocyte surface markers following fixation. *Cytometry Part A*, 71A, 379–385.
- Welker, L., Jörres, R. A., Costabel, U., & Magnussen, H. (2004). Predictive value of BAL cell differentials in the diagnosis of interstitial lung diseases. *The European Respiratory Journal*, 24, 1000–1006.

How to cite this article: Eidhof HHM, Gratama JW, Mulder AHL. Comparison of three methods to stabilize bronchoalveolar lavage cells for flowcytometric analysis. *Cytometry*. 2020;1–7. <https://doi.org/10.1002/cyto.b.21883>